http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
차량용 첨단주행보조시스템(ADAS) 확산요인 분석 및 시사점
허필선(Heo Pil Sun) 한국통신학회 2009 한국통신학회 학술대회논문집 Vol.2009 No.6
자동차-IT 융합 신산업은 첨단 IT 신기술을 기반으로 자동차의 센서 및 전자장치가 지능적, 유기적으로 상호작용하여 운전자의 안전 및 편의성을 증대시켜 최적의 운전환경을 제공하고, 미래형 자동차 산업에 부가가치를 창출하는 산업이다. 자동차와 IT기술의 결합으로 인한 융 복합 부품기술 발전으로 미래 기술 선점 및 유관산업으로 시너지 효과의 극대화도 도모할 수 있다. 최근 자동차-IT 융합의 중요 분야 중 하나인 ADAS(첨단주행보조시스템)에 대한 관심이 고조되고 있으며, 소비자의 안전 및 차량 보호에 대한 기대에 부응하여 차량 제조업체들은 다양한 ADAS 시스템을 적용하고 있으나, 아직까지는 고가차량에서 옵션으로 제공되고 있는 상황이다. 이에 본고에서는 향후 차량의 고부가가치화에 중요한 역할을 할 것으로 기대되며, 자동차-IT 융합의 핵심 분야가 될 차량용 ADAS 시스템의 시장 확산요인 분석을 통해 산업 활성화를 위한 정책적 시사점을 도출하고자 한다.
정보통신기기 상호인정협정(MRA) 추진대상국 분류 및 우선순위 설정
허필선 ( Pil Sun Heo ),박용재 ( Yong Jae Park ),임광선 ( Kwang Sun Lim ) 국제지역학회 2007 국제지역연구 Vol.11 No.1
WTO/TBT 협정 발표 후 무역에 관한 기술장벽 해소를 위한 국가간 상호인정협정(MRA)이 전 세계적으로 확대되고 있다. 주요 선진국들은 자국 산업의 경쟁력 향상을 위해 MRA를 적극 활용하고 있고, 기타 후발 국가들도 자국 제도를 개선하는 등 MRA 참여준비를 본격화 하는 중이다. 이런 국제적 추세 속에서 우리나라도 FTA MRA, APEC TEL MRA 등 다자간, 양자간 MRA에 대한 본격 추진의지를 가지고 이미 몇몇 국가와는 MRA 1단계를 체결하였다. 하지만 향후에는 MRA 체결 상대국 결정절차에 대한 논리적 근거를 확보하고, MRA 체결 가능 대상국별 추진환경의 상이함을 인식하여 국가별·그룹별 맞춤형 MRA 전략 수립이 필요하다. 이에 본고에서는 국가간 MRA 체결에 영향을 미치는 요인을 경제적, 기술적, 정책적, 산업적 측면으로 구분·활용하여 MRA 추진 가능국을 그룹화하고, 우선순위를 설정하여 향후 MRA 체결 추진방안 수립에 기여코자 한다. Since WTO/TBT agreement was announced, Mutual Recognition Arrangement(MRA) to solve technology barriers on overseas trade has been extended all over the world. The leading developed countries positively have been making use of MRA for strengthening their industry competitiveness, and other less advanced countries are making a full-scale arrangement for MRA participation by reforming their system. In this tendency of the world, the republic of Korea, which has the strong will of promoting MRA for example, FTA MRA, APEC TEL MRA, bilateral MRA, multinational recognition arrangement, has already signed 1st stage agreement of MRA with several countries. Hereafter, it is strongly necessary to set up customized MRA strategies in country or group categories by securing logical basis on the agreement procedure of MRA and recognizing the environmental difference among countries which have a possibility of MRA. This article is to establish the plan and the strategy for promoting MRA contract in the future, by classifying the factors in economy, technology, policy, and industry which influence on MRA contract between countries, by making full use of them, and by grouping MRA possible countries and prioritizing the list.
( Sun Young Jo ),( Chang Il Kim ),( Hong Pil Jeong ),( Han Him Jeong ),( Jae Wan Go ),( Eun Phil Heo ) 대한피부과학회 2020 대한피부과학회 학술발표대회집 Vol.72 No.1
Background: Diphenylcyclopropenone (DPCP) is used for the treatment of extensive alopecia areata (AA). Many studies have been conducted to evaluate its efficacy; however, only a few have evaluated the efficacy of DPCP as a maintenance therapy after remission. Objectives: In this study, we investigated variable factors affecting the efficacy of DPCP immunotherapy and relapse in patients with extensive AA treated with DPCP. Methods: Patients, with and without maintenance treatment, who obtained a complete response and were followed up long-term, were included in the study. We retrospectively reviewed the medical records of 82 patients with extensive AA, who were treated with DPCP immunotherapy for at least 3 months between January 2004 and February 2018. Results: Of the 82 patients, 38 (46.34%) showed a complete response. Variables associated with treatment response were age at onset of AA, duration of current episode, extent of hair loss at first visit, subtypes of AA, history of atopic diseases, age at initiation, and duration of DPCP immunotherapy. Of the 38 patients showing a complete response, 26 (68.42%) received maintenance treatment. Patients on maintenance therapy experienced a low relapse rate (P = 0.034; HR = 0.28, 95% CI, 0.08-0.91). Conclusion: We show that topical DPCP can be used to maintain AA remission and propose the continuation of treatment in patients with AA even after obtaining a complete response.
Bacterial Expression and Purification of Human Papillomavirus Type 18 L1
Pil-Soo Seo,Sun-Yeon Heo,Eun Jong Han,서정우,Shin-Je Ghim,Chul Ho Kim 한국생물공학회 2009 Biotechnology and Bioprocess Engineering Vol.14 No.2
The human papillomavirus (HPV) 18 L1 gene, which encodes the L1 major capsid protein, was isolated from a female patient in Pusan, Korea Republic and was cloned into pGEX-4T-1 vector. The HPV-18L1 gene was expressed in Escherichia coli as a fusion protein with a glutathione-S-transferase (GST) tag. The soluble recombinant fusion protein, GST-18 L1 fusion, was isolated to high purity. HPV-18 L1 was purified from the GST-18 L1 fusant after biotinylated thrombin cleavage, and then the treated thrombin was removed serially using streptavidin conjugated resin. The purified HPV-18 L1 was confirmed by western blotting using a rabbit anti-denatured papillomavirus polyclonal antibody. The virus-like particles (VLP) from the purified full-length 18 L1 protein without any extra amino acid sequences was observed through the analysis of the electron microscope. This is the first study to report the expression and purification of HPV-18 L1 in E.coli. This expression and purification system offers a simple method of expressing and purifying HPV L1 protein, and could potentially be an effective route for the development and manufacturing of highly purified HPV-18 L1-based cervical cancer vaccines The human papillomavirus (HPV) 18 L1 gene, which encodes the L1 major capsid protein, was isolated from a female patient in Pusan, Korea Republic and was cloned into pGEX-4T-1 vector. The HPV-18L1 gene was expressed in Escherichia coli as a fusion protein with a glutathione-S-transferase (GST) tag. The soluble recombinant fusion protein, GST-18 L1 fusion, was isolated to high purity. HPV-18 L1 was purified from the GST-18 L1 fusant after biotinylated thrombin cleavage, and then the treated thrombin was removed serially using streptavidin conjugated resin. The purified HPV-18 L1 was confirmed by western blotting using a rabbit anti-denatured papillomavirus polyclonal antibody. The virus-like particles (VLP) from the purified full-length 18 L1 protein without any extra amino acid sequences was observed through the analysis of the electron microscope. This is the first study to report the expression and purification of HPV-18 L1 in E.coli. This expression and purification system offers a simple method of expressing and purifying HPV L1 protein, and could potentially be an effective route for the development and manufacturing of highly purified HPV-18 L1-based cervical cancer vaccines